Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study

Neurology

Volumn 78, Issue 15, 2012, Pages 1171-1178

  Waubant, E ^a   Pelletier, D ^a   Mass, M ^b   Cohen, J A ^c   Kita, M ^d   Cross, A ^e   Bar Or, A ^f   Vollmer, T ^g   Racke, M ^h   Stuve O ^h,r   Schwid, S ⁱ   Goodman, A ⁱ   Kachuck, N ^j   Preiningerova, J ^k   Weinstock Guttman, B ^l   Calabresi, P A ^m   Miller, A ⁿ   Mokhtarani, M ^o   Ikle D ^p   Murphy, S ^p   Kopetskie, H ^p   Ding, L ^q   Rosenberg, E ^q   Spencer, C ^a   Zamvil, S S ^a   Bourdette, D ^r   Egan, R ^r   Stone, L ^r   Elliott, M ^r   Parks, B J ^r   Campagnolo, D ^r   Frohman, E ^r   Segal, B ^r   Weiner, L ^r   Carrithers, M ^r   Kerr, D ^r   Lublin, F ^r   Sayre, P ^r   Hayes, D ^r   Gao, W ^r   Adah, S ^r   Neuenburg, J ^r   Bromstead, C ^r   Olinger, L ^r   Mullen, B ^r   Jamison, R ^r   Speth, K ^r   Saljooqi, K ^r   Phan, P ^r   Phippard, D ^r   Seyfert Margolis, V ^r   Bourcier, K ^r   Debnam, T ^r   Romaine, J ^r   Wolin, S ^r   O'Dale, B ^r   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Virginia Mason Health System   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g BARROW NEUROLOGICAL INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l JACOBS NEUROLOGICAL INSTITUTE   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o Immune Tolerance Network   (United States)

^p RHO INC   (United States)

^q NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; GADOLINIUM; PLACEBO;

ARTICLE; BRAIN DAMAGE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; UNSPECIFIED SIDE EFFECT;

EID: 84860723016     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824f7fdd     Document Type: Article

References (23)

1. Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 2002;59:970-971.
2. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84. (Pubitemid 35291443)
3. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197:725-733. (Pubitemid 36350867)
4. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006;203:401-412. (Pubitemid 43290849)
5. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608. (Pubitemid 38625664)
6. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008;71: 1390-1395.
7. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008;3:e1928.
8. Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy. Mult Scler 2010;16:450-454.
9. Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: A double-blind randomized controlled trial. Mult Scler 2010;16:848-854.
10. Sorensen PS, Lycke J, Eralinna JP, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsingremitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial. Lancet Neurol 2011;10:691-701.
11. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
13. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882. (Pubitemid 29219261)
14. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-676. (Pubitemid 37103016)
15. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466-475. (Pubitemid 32440803)
16. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704. (Pubitemid 29530342)
17. Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsingremitting multiple sclerosis. Neurology 2008;70:1092-1097. (Pubitemid 351464765)
18. Stüve O, Youssef S, Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006;116:1037-1044.
19. Zamvil SS, Steinman L. Combining statins with interferon beta in multiple sclerosis: Think twice, it might not be all right. Lancet Neurol 2011;10:672-673.
20. Dhawan N, Reder AT. Statins block interferon signaling in human immune cells: Potential loss of the therapeutic effect of IFN-beta in multiple sclerosis. Neurology 2007; 68(suppl 1):A364. Abstract.
21. Lee SJ, Qin H, Benveniste EN. Simvastatin inhibits IFNgamma-induced CD40 gene expression by suppressing STAT-1alpha. J Leukoc Biol 2007;82:436-447. (Pubitemid 47230655)
22. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421. (Pubitemid 24217131)
23. Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009;72:1989-1993.